At present, the company can make and supply alectinib, palbociclib, pemigatinib, loratinib, rimegepant and other APIs, including 5-nitroisophthalic acid, 5-aminoisophthalic acid, 2-nitro-4-fluoroaniline, 3-indole-3-carboxylic acid, methyl indole-3-carboxylate, 4-amino-2, 6-dichloropyrimidine, 2-nitro-4-methylsulfonyltoluene and other intermediates.